Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction
Background Elevated interleukin-6 (IL-6) levels are present in patients with New York Heart Association (NYHA) class III and IV congestive heart failure (CHF) and are associated with a poor prognosis. We sought to determine whether elevated IL-6 levels are also present in patients with left ventricu...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 2001-03, Vol.141 (3), p.435-438 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 438 |
|---|---|
| container_issue | 3 |
| container_start_page | 435 |
| container_title | The American heart journal |
| container_volume | 141 |
| creator | Raymond, Ronald J. Dehmer, Gregory J. Theoharides, Theoharis C. Deliargyris, Efthymios N. |
| description | Background Elevated interleukin-6 (IL-6) levels are present in patients with New York Heart Association (NYHA) class III and IV congestive heart failure (CHF) and are associated with a poor prognosis. We sought to determine whether elevated IL-6 levels are also present in patients with left ventricular (LV) dysfunction but without clinical symptoms. Methods Blood samples were obtained from the femoral artery of 58 patients who underwent cardiac catheterization for recognized clinical indications. In a subgroup of 44 patients, samples were also obtained from the femoral vein, the left main coronary artery, and the coronary sinus. Patients with prior coronary artery bypass surgery, recent acute coronary syndrome, or steroid therapy were excluded. All samples were obtained before heparin or contrast administration. IL-6 was measured by enzyme-linked immunosorbent assay and values are expressed in picograms per milliliter. Results Three groups of patients were identified: controls, no CHF, LV ejection fraction ≥0.55 (n = 32); asymptomatic LV systolic dysfunction, no CHF, LV ejection fraction |
| doi_str_mv | 10.1067/mhj.2001.113078 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76979175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870301956583</els_id><sourcerecordid>76979175</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-3cd282ebdab5009b563afaebdc069f268bfacf2356daf83a5a696f6bcd0dedac3</originalsourceid><addsrcrecordid>eNp1kE1r3DAQhkVpaLZpz7kFQyE3b_SxlqxjCElaWOglPYuxNCJKZXsryRv230dhl_bUk5h3Hr0MDyGXjK4ZlepmfH5Zc0rZmjFBVf-BrBjVqpVqs_lIVpRS3vaKinPyOeeXOkrey0_knDEu2GbDVwTuI-6hoGvCVDBFXH6HqZVNTTHmGjY7KAGnkpvXUJ4byIdxV-axhrZCvjT7ukzBLhFSkw-5zLFu3CH7ZbIlzNMXcuYhZvx6ei_Ir4f7p7vv7fbn44-7221rhWKlFdbxnuPgYOgo1UMnBXios6VSey77wYP1XHTSge8FdCC19HKwjjp0YMUFuT727tL8Z8FczBiyxRhhwnnJRkmtNFNdBW-OoE1zzgm92aUwQjoYRs27VVOtmner5mi1_rg6VS_DiO4ff9JYgW8nALKF6BNMNuS_nK5dQldKH6lqFvcBk8m2qrXoQkJbjJvDf094A6ghloM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76979175</pqid></control><display><type>article</type><title>Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Raymond, Ronald J. ; Dehmer, Gregory J. ; Theoharides, Theoharis C. ; Deliargyris, Efthymios N.</creator><creatorcontrib>Raymond, Ronald J. ; Dehmer, Gregory J. ; Theoharides, Theoharis C. ; Deliargyris, Efthymios N.</creatorcontrib><description>Background Elevated interleukin-6 (IL-6) levels are present in patients with New York Heart Association (NYHA) class III and IV congestive heart failure (CHF) and are associated with a poor prognosis. We sought to determine whether elevated IL-6 levels are also present in patients with left ventricular (LV) dysfunction but without clinical symptoms. Methods Blood samples were obtained from the femoral artery of 58 patients who underwent cardiac catheterization for recognized clinical indications. In a subgroup of 44 patients, samples were also obtained from the femoral vein, the left main coronary artery, and the coronary sinus. Patients with prior coronary artery bypass surgery, recent acute coronary syndrome, or steroid therapy were excluded. All samples were obtained before heparin or contrast administration. IL-6 was measured by enzyme-linked immunosorbent assay and values are expressed in picograms per milliliter. Results Three groups of patients were identified: controls, no CHF, LV ejection fraction ≥0.55 (n = 32); asymptomatic LV systolic dysfunction, no CHF, LV ejection fraction <0.55 (n = 14); and CHF, pulmonary edema (n = 12). IL-6 levels were higher at all sampling sites in both the asymptomatic LV systolic dysfunction and CHF groups compared with controls with the IL-6 levels inversely related to LV ejection fraction. Conclusions Elevated IL-6 levels are present in patients with LV dysfunction even in the absence of the clinical syndrome of CHF. These data suggest that IL-6 may be involved in the progression of subclinical LV dysfunction to clinical CHF. IL-6 may be a marker of patients at risk for progression to clinical CHF or a novel target for therapeutic intervention. (Am Heart J 2001;141:435-8.)</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1067/mhj.2001.113078</identifier><identifier>PMID: 11231442</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Biological and medical sciences ; Cardiology. Vascular system ; Female ; Heart ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Humans ; Interleukin-6 - analysis ; Male ; Medical sciences ; Middle Aged ; Systole - physiology ; Ventricular Dysfunction, Left - blood ; Ventricular Dysfunction, Left - physiopathology</subject><ispartof>The American heart journal, 2001-03, Vol.141 (3), p.435-438</ispartof><rights>2001 Mosby, Inc.</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-3cd282ebdab5009b563afaebdc069f268bfacf2356daf83a5a696f6bcd0dedac3</citedby><cites>FETCH-LOGICAL-c371t-3cd282ebdab5009b563afaebdc069f268bfacf2356daf83a5a696f6bcd0dedac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1067/mhj.2001.113078$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=900139$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11231442$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raymond, Ronald J.</creatorcontrib><creatorcontrib>Dehmer, Gregory J.</creatorcontrib><creatorcontrib>Theoharides, Theoharis C.</creatorcontrib><creatorcontrib>Deliargyris, Efthymios N.</creatorcontrib><title>Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background Elevated interleukin-6 (IL-6) levels are present in patients with New York Heart Association (NYHA) class III and IV congestive heart failure (CHF) and are associated with a poor prognosis. We sought to determine whether elevated IL-6 levels are also present in patients with left ventricular (LV) dysfunction but without clinical symptoms. Methods Blood samples were obtained from the femoral artery of 58 patients who underwent cardiac catheterization for recognized clinical indications. In a subgroup of 44 patients, samples were also obtained from the femoral vein, the left main coronary artery, and the coronary sinus. Patients with prior coronary artery bypass surgery, recent acute coronary syndrome, or steroid therapy were excluded. All samples were obtained before heparin or contrast administration. IL-6 was measured by enzyme-linked immunosorbent assay and values are expressed in picograms per milliliter. Results Three groups of patients were identified: controls, no CHF, LV ejection fraction ≥0.55 (n = 32); asymptomatic LV systolic dysfunction, no CHF, LV ejection fraction <0.55 (n = 14); and CHF, pulmonary edema (n = 12). IL-6 levels were higher at all sampling sites in both the asymptomatic LV systolic dysfunction and CHF groups compared with controls with the IL-6 levels inversely related to LV ejection fraction. Conclusions Elevated IL-6 levels are present in patients with LV dysfunction even in the absence of the clinical syndrome of CHF. These data suggest that IL-6 may be involved in the progression of subclinical LV dysfunction to clinical CHF. IL-6 may be a marker of patients at risk for progression to clinical CHF or a novel target for therapeutic intervention. (Am Heart J 2001;141:435-8.)</description><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Female</subject><subject>Heart</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Humans</subject><subject>Interleukin-6 - analysis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Systole - physiology</subject><subject>Ventricular Dysfunction, Left - blood</subject><subject>Ventricular Dysfunction, Left - physiopathology</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1r3DAQhkVpaLZpz7kFQyE3b_SxlqxjCElaWOglPYuxNCJKZXsryRv230dhl_bUk5h3Hr0MDyGXjK4ZlepmfH5Zc0rZmjFBVf-BrBjVqpVqs_lIVpRS3vaKinPyOeeXOkrey0_knDEu2GbDVwTuI-6hoGvCVDBFXH6HqZVNTTHmGjY7KAGnkpvXUJ4byIdxV-axhrZCvjT7ukzBLhFSkw-5zLFu3CH7ZbIlzNMXcuYhZvx6ei_Ir4f7p7vv7fbn44-7221rhWKlFdbxnuPgYOgo1UMnBXios6VSey77wYP1XHTSge8FdCC19HKwjjp0YMUFuT727tL8Z8FczBiyxRhhwnnJRkmtNFNdBW-OoE1zzgm92aUwQjoYRs27VVOtmner5mi1_rg6VS_DiO4ff9JYgW8nALKF6BNMNuS_nK5dQldKH6lqFvcBk8m2qrXoQkJbjJvDf094A6ghloM</recordid><startdate>20010301</startdate><enddate>20010301</enddate><creator>Raymond, Ronald J.</creator><creator>Dehmer, Gregory J.</creator><creator>Theoharides, Theoharis C.</creator><creator>Deliargyris, Efthymios N.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010301</creationdate><title>Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction</title><author>Raymond, Ronald J. ; Dehmer, Gregory J. ; Theoharides, Theoharis C. ; Deliargyris, Efthymios N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-3cd282ebdab5009b563afaebdc069f268bfacf2356daf83a5a696f6bcd0dedac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Female</topic><topic>Heart</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Humans</topic><topic>Interleukin-6 - analysis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Systole - physiology</topic><topic>Ventricular Dysfunction, Left - blood</topic><topic>Ventricular Dysfunction, Left - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raymond, Ronald J.</creatorcontrib><creatorcontrib>Dehmer, Gregory J.</creatorcontrib><creatorcontrib>Theoharides, Theoharis C.</creatorcontrib><creatorcontrib>Deliargyris, Efthymios N.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raymond, Ronald J.</au><au>Dehmer, Gregory J.</au><au>Theoharides, Theoharis C.</au><au>Deliargyris, Efthymios N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2001-03-01</date><risdate>2001</risdate><volume>141</volume><issue>3</issue><spage>435</spage><epage>438</epage><pages>435-438</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background Elevated interleukin-6 (IL-6) levels are present in patients with New York Heart Association (NYHA) class III and IV congestive heart failure (CHF) and are associated with a poor prognosis. We sought to determine whether elevated IL-6 levels are also present in patients with left ventricular (LV) dysfunction but without clinical symptoms. Methods Blood samples were obtained from the femoral artery of 58 patients who underwent cardiac catheterization for recognized clinical indications. In a subgroup of 44 patients, samples were also obtained from the femoral vein, the left main coronary artery, and the coronary sinus. Patients with prior coronary artery bypass surgery, recent acute coronary syndrome, or steroid therapy were excluded. All samples were obtained before heparin or contrast administration. IL-6 was measured by enzyme-linked immunosorbent assay and values are expressed in picograms per milliliter. Results Three groups of patients were identified: controls, no CHF, LV ejection fraction ≥0.55 (n = 32); asymptomatic LV systolic dysfunction, no CHF, LV ejection fraction <0.55 (n = 14); and CHF, pulmonary edema (n = 12). IL-6 levels were higher at all sampling sites in both the asymptomatic LV systolic dysfunction and CHF groups compared with controls with the IL-6 levels inversely related to LV ejection fraction. Conclusions Elevated IL-6 levels are present in patients with LV dysfunction even in the absence of the clinical syndrome of CHF. These data suggest that IL-6 may be involved in the progression of subclinical LV dysfunction to clinical CHF. IL-6 may be a marker of patients at risk for progression to clinical CHF or a novel target for therapeutic intervention. (Am Heart J 2001;141:435-8.)</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>11231442</pmid><doi>10.1067/mhj.2001.113078</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 2001-03, Vol.141 (3), p.435-438 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76979175 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Biological and medical sciences Cardiology. Vascular system Female Heart Heart failure, cardiogenic pulmonary edema, cardiac enlargement Humans Interleukin-6 - analysis Male Medical sciences Middle Aged Systole - physiology Ventricular Dysfunction, Left - blood Ventricular Dysfunction, Left - physiopathology |
| title | Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T00%3A52%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20interleukin-6%20levels%20in%20patients%20with%20asymptomatic%20left%20ventricular%20systolic%20dysfunction&rft.jtitle=The%20American%20heart%20journal&rft.au=Raymond,%20Ronald%20J.&rft.date=2001-03-01&rft.volume=141&rft.issue=3&rft.spage=435&rft.epage=438&rft.pages=435-438&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1067/mhj.2001.113078&rft_dat=%3Cproquest_cross%3E76979175%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76979175&rft_id=info:pmid/11231442&rft_els_id=S0002870301956583&rfr_iscdi=true |